Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Assessing the effect of adding chelating agent (Tris-CaEDTA) to nebulised tobramycin for improving bacterial killing and lung function in cystic fibrosis patients with Pseudomonas aeruginosa lung infection.

Assessing the effect of adding chelating agent (Tris-CaEDTA) to nebulised tobramycin for improving bacterial killing and lung function in cystic fibrosis patients with Pseudomonas aeruginosa lung infection.

Resource Type

CF Research News

Authors

Ramaa Puvvadi, Helga Mikkelsen, Lucy McCahon, Samantha Grogan, William Ditcham, David W Reid, Iain Lamont, Stephen M Stick, Barry Clements

References

J Cyst Fibros. 2020 Dec 16;S1569-1993(20)30936-X. doi: 10.1016/j.jcf.2020.12.004.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

EDTA [3]
Pseudomonas aeruginosa [4]
Tobramycin [5]

Date

Wednesday, December 16, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [6]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/assessing-effect-adding-chelating-agent-tris-caedta-nebulised

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-20-00314R3_Puvvadi_FINAL_310121.pdf [2] https://pubmed.ncbi.nlm.nih.gov/33341406/ [3] https://www.ecfs.eu/research-article-keywords/edta [4] https://www.ecfs.eu/research-article-keywords/pseudomonas-aeruginosa [5] https://www.ecfs.eu/research-article-keywords/tobramycin [6] https://www.ecfs.eu/resource-guideline-type/other-guidelines